Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00202488 · ClinicalTrials.gov registry record · Phase 2

The Effect of H. Pylori Infection on Iron Metabolism

A Phase 2 study of Iron Deficiency Anemia and Helicobacter Pylori Infection, sponsored by Seattle Institute for Biomedical and Clinical Research.

Completed
Registry status
Phase 2
Development phase
39
Enrollment target
1
Study location

NCT00202488 is a Phase 2 study of Iron Deficiency Anemia and Helicobacter Pylori Infection that has completed, run by Seattle Institute for Biomedical and Clinical Research. The registered enrollment target is 39 participants, below the 192-participant average among 24 other Iron Deficiency Anemia trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00202488, a Phase 2 study of Iron Deficiency Anemia and Helicobacter Pylori Infection, has completed, sponsored by Seattle Institute for Biomedical and Clinical Research.

COMPLETED
Registry status
Phase 2
Development phase
39 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine if Helicobacter pylori (H. pylori) gastritis results in abnormal iron metabolism in patients with iron deficiency anemia (IDA), and to determine if this is due to strain variations in the H. pylori organism.

Interventions

  • DRUG H. pylori treatment

Study Locations (1)

Washington

  • VA Puget Sound Health Care System - Seattle

Trial Details

FieldValue
Enrollment Target 39 participants
Start Date 2002-11
Est. Completion 2007-09
Phase Phase 2

What the Registry Record Tells You About NCT00202488

The ClinicalTrials.gov registry entry for NCT00202488 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 192-participant average among 24 other Iron Deficiency Anemia trials with a reported enrollment target (80% lower). The listed sponsor is Seattle Institute for Biomedical and Clinical Research, which has 43 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Iron Deficiency Anemia appearing as the primary indexed condition, and to 1 intervention - of which H. pylori treatment is the first listed.

NCT00202488 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT00202488 about?

NCT00202488 is a clinical study titled "The Effect of H. Pylori Infection on Iron Metabolism". The purpose of this study is to determine if Helicobacter pylori (H. pylori) gastritis results in abnormal iron metabolism in patients with iron deficiency anemia (IDA), and to determine if this is due to strain variations in the H. pylori organism.

What is the current status of trial NCT00202488?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2002-11. Estimated completion is 2007-09.

What conditions does trial NCT00202488 study?

This clinical trial studies the following conditions: Iron Deficiency Anemia, Helicobacter Pylori Infection.

What interventions are being tested in trial NCT00202488?

The interventions under investigation include: H. pylori treatment (DRUG).

Who is sponsoring clinical trial NCT00202488?

This trial is sponsored by Seattle Institute for Biomedical and Clinical Research, which has 43 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00202488 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Iron Deficiency Anemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.